Assertio Holdings (ASRT) Change in Accured Expenses (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Change in Accured Expenses came in at -$650000.0 in Q1 2026, down 107.26% year-on-year from $9.0 million in Q1 2025, and up 93.47% quarter-over-quarter from -$10.0 million in Q4 2025.
Assertio Holdings (ASRT) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Change in Accured Expenses across 8 years of filings, most recently posting -$650000.0 for Q1 2026.
- Change in Accured Expenses for Q1 2026 came in at -$650000.0, down 107.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.9 million (down 392.34% YoY), and the FY2025 annual result was -$13.3 million, down 958.28% from the prior year.
- Change in Accured Expenses came in at -$650000.0 for Q1 2026 at Assertio Holdings, up from -$10.0 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $9.0 million in Q1 2025 to a low of -$26.4 million in Q3 2023.
- The 5-year median for Change in Accured Expenses is -$650000.0 (2026), against an average of -$2.6 million.
- Peak annual rise in Change in Accured Expenses reached 6782.09% in 2025, while the deepest fall reached 1542.74% in 2025.
- Assertio Holdings' Change in Accured Expenses stood at $7.1 million in 2022, then tumbled by 210.24% to -$7.8 million in 2023, then soared by 92.26% to -$606000.0 in 2024, then slumped by 1542.74% to -$10.0 million in 2025, then soared by 93.47% to -$650000.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$650000.0 (Q1 2026), -$10.0 million (Q4 2025), and -$10.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Accured Exp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 23.00 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | 10.02 Mn |
| 10 | Assertio Holdings | 150.78 Mn | 79.21 Mn | 7.22 Mn | -650,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -650,000.00 |
| Mar 31, 2026 | -650,000.00 |
| Dec 31, 2025 | -9.96 Mn |
| Dec 31, 2025 | -9.96 Mn |
| Sep 30, 2025 | -10.35 Mn |
| Sep 30, 2025 | -10.35 Mn |
| Jun 30, 2025 | -1.94 Mn |
| Jun 30, 2025 | -1.94 Mn |
| Mar 31, 2025 | 8.95 Mn |
| Mar 31, 2025 | 8.95 Mn |
| Dec 31, 2024 | -606,000.00 |
| Dec 31, 2024 | -606,000.00 |
| Sep 30, 2024 | 977,000.00 |
| Sep 30, 2024 | 977,000.00 |
| Jun 30, 2024 | -1.49 Mn |
| Jun 30, 2024 | -1.49 Mn |
| Mar 31, 2024 | -134,000.00 |
| Mar 31, 2024 | -134,000.00 |
| Dec 31, 2023 | -7.83 Mn |
| Dec 31, 2023 | -7.83 Mn |